LeMaitre Vascular stock (US52567J1079): Q1 beat and raised 2026 guidance

LeMaitre Vascular reported Q1 2026 revenue of $66.55 million, up 11%, with net income of $15.68 million. The company raised full-year sales guidance to $277-283 million and approved a $0.25 quarterly dividend payable June 4.

LeMaitre Vascular stock reacted to first-quarter 2026 results released earlier in May, showing revenue of US$66.55 million, a 11% increase year-over-year, and net income of US$15.68 million, according to Simply Wall St as of May 2026. Management raised full-year 2026 sales guidance to US$277-283 million and EPS to US$2.93-US$3.08. The board also approved a quarterly dividend of US$0.25 per share, payable on June 4, 2026.

The stock traded at $117.40 on Nasdaq as of recent data, with a market cap of $2.24 billion and P/E ratio of 36.23, per MarketBeat as of May 2026. All geographic regions posted record sales: EMEA up 20%, APAC up 18%, Americas up 7%. Product growth was led by grafts at 20%, valvulotomes at 15%, and carotid shunts at 11%, according to The Dividend Guy as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: LeMaitre Vascular, Inc.
• Sector/industry: Medical devices (peripheral vascular)
• Headquarters/country: Burlington, Massachusetts, USA
• Core markets: Americas, EMEA, APAC
• Key revenue drivers: Grafts, valvulotomes, carotid shunts
• Home exchange/listing venue: Nasdaq (LMAT)
• Trading currency: USD

LeMaitre Vascular: core business model

LeMaitre Vascular develops, manufactures, and markets medical devices for peripheral vascular disease treatment. The portfolio includes vascular surgical instruments, grafts, patches, catheters, and embolic protection devices. Headquartered in Burlington, Massachusetts, the company serves surgeons treating conditions like aortic aneurysms and carotid disease.

Products target niche vascular procedures, emphasizing innovation in areas like valvulotomes for vein treatment and shunts for carotid endarterectomy. This focus allows LeMaitre Vascular to maintain high margins in a specialized segment of the medtech industry.

Main revenue and product drivers for LeMaitre Vascular

Grafts led Q1 2026 growth at 20%, reflecting strong demand for vascular reconstruction products. Valvulotomes grew 15%, driven by procedures for chronic venous insufficiency. Carotid shunts increased 11%, supported by steady neurosurgical volumes. Geographic expansion boosted EMEA and APAC sales significantly.

Revenue for Q1 2026 reached $66.55 million, with adjusted EPS at $0.68, up 42% year-over-year per reports. Full-year guidance upgrade signals confidence in sustained product momentum and market penetration.

Industry trends and competitive position

The peripheral vascular device market benefits from aging populations and rising cardiovascular disease prevalence in the US and globally. LeMaitre Vascular holds a strong position in grafts and valvulotomes, differentiating through specialized offerings versus broader competitors.

US investors note the company's exposure to domestic procedure growth, with Americas revenue up 7% in Q1. Institutional ownership includes Conestoga Capital Advisors at 6.46% and First Trust Advisors at 4.37%, per MarketBeat data.

Why LeMaitre Vascular matters for US investors

Listed on Nasdaq, LeMaitre Vascular provides US investors direct access to a pure-play peripheral vascular leader. Its Massachusetts base and focus on US procedure volumes tie performance to American healthcare spending trends.

The dividend yield of 1.02% adds appeal for income-focused portfolios tracking medtech stability.

Conclusion

LeMaitre Vascular's Q1 results and raised 2026 guidance underscore operational strength across products and regions. The dividend continuation supports shareholder returns amid growth prospects. Investors monitor execution on outlook and vascular market dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.